文献速递细菌感染、耐药与抗菌药物

头孢吡肟-恩美唑巴坦对碳青霉烯耐药革兰阴性菌的体外活性

In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives.
PubMed 文献 · Clin Microbiol Infect · 2024-10-05

本研究采用微量肉汤稀释法,检测头孢吡肟-恩美唑巴坦等β-内酰胺/β-内酰胺酶抑制剂组合对2212株碳青霉烯耐药肠杆菌目(含2089株产碳青霉烯酶)、50株铜绿假单胞菌和30株鲍曼不动杆菌的体外活性。产OXA-48菌株对头孢吡肟-恩美唑巴坦敏感率为96.7%,与头孢他啶-阿维巴坦的99.5%相近;对产KPC菌株两者敏感率分别为63.3%和95.9%。作者认为需体内实验确认其可否作为产OXA-48菌感染时头孢他啶-阿维巴坦的替代选择。

要点

  • 产OXA-48菌株对头孢吡肟-恩美唑巴坦敏感率96.7%,与头孢他啶-阿维巴坦的99.5%相近。
  • 产KPC菌株对头孢吡肟-恩美唑巴坦敏感率63.3%,低于头孢他啶-阿维巴坦的95.9%。
  • 恩美唑巴坦对金属β-内酰胺酶无抑制活性。

核心结论

  • 产OXA-48菌株对头孢吡肟-恩美唑巴坦呈高敏感,与头孢他啶-阿维巴坦相似,包括共产超广谱β-内酰胺酶或AmpC的OXA-48产酶株。
  • 作者认为需开展体内实验,以确认头孢吡肟-恩美唑巴坦是否可能成为产OXA-48菌感染治疗中头孢他啶-阿维巴坦的相关替代选择。

研究设计与样本

  • 采用微量肉汤稀释法测定头孢吡肟、头孢吡肟-恩美唑巴坦、头孢他啶、头孢他啶-阿维巴坦、美罗培南、美罗培南-伐博巴坦、亚胺培南、亚胺培南-瑞来巴坦和厄他培南的最低抑菌浓度。
  • 菌株包括2212株碳青霉烯耐药肠杆菌目(其中2089株产碳青霉烯酶:1000株OXA-48样、49株KPC、697株NDM、180株VIM、1株IMP、9株IMI、158株产多种碳青霉烯酶;另123株不产碳青霉烯酶)、50株铜绿假单胞菌和30株鲍曼不动杆菌。
  • 菌株来源于法国国家参考中心,接收时间为2023年3月1日至2023年8月31日,所有菌株均完成全基因组测序。

主要发现

  • 证实恩美唑巴坦对金属β-内酰胺酶无抑制活性。
  • 产OXA-48菌株对头孢吡肟-恩美唑巴坦与头孢他啶-阿维巴坦的敏感率分别为96.7%与99.5%。
  • 碳青霉烯耐药肠杆菌目非产碳青霉烯酶株和产KPC株对头孢吡肟-恩美唑巴坦的敏感率分别为66.9%和63.3%。
  • 上述两类菌株对头孢他啶-阿维巴坦的敏感率分别为96.7%和95.9%,对亚胺培南-瑞来巴坦分别为93.4%和95.9%,对美罗培南-伐博巴坦分别为95.9%和98.0%。
  • 对头孢他啶-阿维巴坦耐药的KPC变异株,头孢吡肟-恩美唑巴坦的最低抑菌浓度≤0.25 mg/L。

局限性

  • 作者指出需开展体内实验,以确认头孢吡肟-恩美唑巴坦是否可能成为产OXA-48菌感染治疗中头孢他啶-阿维巴坦的相关替代选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cefepime-enmetazobactam is a new β-lactam/βlactamase inhibitor combination with broad-spectrum activity against multidrug-resistant Enterobacterales, including extended-spectrum β-lactamase producers. This study evaluated the in vitro activity of cefepime-enmetazobactam towards a collection of carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa and Acinetobacter baumannii compared to the other β-lactam/β-lactamase inhibitor combinations. METHODS: The MIC of cefepime, cefepime-enmetazobactam, ceftazidime, ceftazidime-avibactam, meropenem, meropenem-vaborbactam, imipenem, imipenem-relebactam, and ertapenem were determined by broth microdilution on 2212 CRE, including 2089 carbapenemase producers (1000 OXA-48-like, 49 KPC, 697 NDM, 180 VIM, 1 IMP, 9 IMI, and 158 multiple carbapenemases) and 123 CRE that do not produce carbapenemase received at the French National Reference Centre (from March 1, 2023 to August 31, 2023), 50 P. aeruginosa, and 30 A. baumannii. All strains were fully sequenced. RESULTS: We confirmed the absence of inhibitory activity of enmetazobactam towards metallo-β-lactamases. Cefepime-enmetazobactam and ceftazidime-avibactam exhibited a similar susceptibility (96.7% vs. 99.5%, respectively) on OXA-48-producers. Cefepime-enmetazobactam exhibited 66.9% and 63.3% susceptibility for CRE non-EPC and KPC, whereas those rates rose to 96.7%/95.9%, 93.4%/95.9%, and 95.9%/98.0% for ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam, respectively. Low MICs (≤0.25 mg/L) were obtained for ceftazidime-avibactam-resistant KPC variants. Cefepime-enmetazobactam did not display a significant added value when compared with cefepime alone on Pseudomonas aeruginosa and Acinetobacter baumannii. DISCUSSION: OXA-48 producers displayed high susceptibility to cefepime-enmetazobactam, which is similar to ceftazidime-avibactam, including for OXA-48 producers that coproduce a ceftazidime hydrolyzing enzyme (extended-spectrum β-lactamases or AmpC). In vivo experiments have to be implemented to confirm if cefepime-enmetazobactam might be a relevant alternative to ceftazidime-avibactam for the treatment of infections caused by OXA-48 producers.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Bonnin RA, Jeannot K, Santerre Henriksen A, et al. In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives. Clin Microbiol Infect. 2024. PMID: 39374655. doi:10.1016/j.cmi.2024.09.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。